Erste Asset Management’s Travere Therapeutics TVTX Stock Holding History

Erste Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-35,600	Closed	-$879K	–	572
2022 Q2	$879K	Hold	35,600	–	–	0.02%	372
2022 Q1	$894K	Hold	35,600	–	–	0.02%	367
2021 Q4	$1.09M	Hold	35,600	–	–	0.02%	349
2021 Q3	$854K	Hold	35,600	–	–	0.02%	348
2021 Q2	$532K	Hold	35,600	–	–	0.01%	403
2021 Q1	$866K	Hold	35,600	–	–	0.02%	341
2020 Q4	$963K	Hold	35,600	–	–	0.03%	339
2020 Q3	$663K	Hold	35,600	–	–	0.02%	332
2020 Q2	$702K	Hold	35,600	–	–	0.03%	320
2020 Q1	$507K	Hold	35,600	–	–	0.03%	306
2019 Q4	$512K	Hold	35,600	–	–	0.02%	327
2019 Q3	$423K	Hold	35,600	–	–	0.02%	329
2019 Q2	$715K	Hold	35,600	–	–	0.04%	276
2019 Q1	$820K	Sell	35,600 -8,400	-19%	-$186K	0.05%	263
2018 Q4	$979K	Buy	+44,000	New	+$1.09M	0.07%	239

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Erste Asset Management's TVTX Position: Q3 2022 in Review

Erste Asset Management sold out of Travere Therapeutics (TVTX) in Q3 2022, closing a stake of 35,600 shares — an estimated $879K sold.

Erste Asset Management first reported a position in TVTX in Q4 2018 and held it in 15 quarters. The position peaked at $1.09M in Q4 2021. 171 funds tracked by Wall St. Rank hold TVTX as of Q3 2022.

Erste Asset Management reported no remaining Travere Therapeutics position as of Q3 2022 after selling out during the quarter.
Erste Asset Management sold 35,600 Travere Therapeutics shares in Q3 2022, an estimated $879K.
Erste Asset Management first reported a position in Travere Therapeutics in Q4 2018 and held it in 15 quarters.
Erste Asset Management's Travere Therapeutics position peaked at $1.09M in Q4 2021.
171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2022.

Based on Erste Asset Management's 13F filing for Q3 2022, filed 26 Nov 2024.